Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Cash Flows From Operating Activities    
Net loss $ (25,527) $ (11,914)
Adjustments to reconcile net income to net cash    
Depreciation and amortization 2,034 3,046
Realignment accrual accretion 142 161
Provision for bad debt, net 16 58
Reversal of contingent consideration accrual 0 (1,557)
Non-cash loss on sale of Pharmakon    6,868
Stock-based compensation 1,791 1,936
Asset impairments 23,517 0
Non-cash facilities realignment 69 0
Other changes in assets and liabilities:    
(Increase) decrease in accounts receivable (1,054) 1,397
Decrease in unbilled costs 638 770
Increase in other current assets (758) (1,797)
(Increase) decrease in other long-term assets (7) 2,617
(Decrease) increase in accounts payable (751) 873
(Decrease) increase in unearned contract revenue (1,381) 2,465
Decrease in accrued salaries and bonus (1,609) (2,381)
(Decrease) increase in accrued liabilities (5,913) 1,817
Decrease in long-term liabilities (1,493) (2,374)
Net cash (used in) provided by operating activities (10,286) 1,985
Cash Flows From Investing Activities    
Purchase of property and equipment (1,112) (343)
Net cash used in investing activities (1,112) (343)
Cash Flows From Financing Activities    
Cash paid for repurchase of restricted shares (156) (16)
Net cash used in financing activities (156) (16)
Net (decrease) increase in cash and cash equivalents (11,554) 1,626
Cash and cash equivalents – beginning 64,337 62,711
Cash and cash equivalents – ending 52,783 64,337
Cash paid for taxes $ 175 $ 37